Data from the nonSD + GHK cohort are not shown because there was no effect
Jan2023
Lv J, Xu S, Meng C, Wang Y, Ji L, Li X, et al
Since 2015, large-scale cardiovascular outcome trials (CVOTs) have demonstrated that sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly reduce the risk of major adverse cardiovascular events, cardiovascular mortality, and heart failure hospitalization in patients with T2DM and established cardiovascular disease or high-risk profiles
Serving Size: 2 Slow Melt Tablets Servings Per Container: 30 Amount Per Serving: L-Glutathione (Reduced Form) 300 mg Other Ingredients: Maltitol, hydroxypropylmethylcellulose, vanilla flavor, pomegranate (Punica granatum) fruit extract, vegetable source magnesium stearate, stevia
Inositol becomes the fat's chauffeur, ensuring it reaches its destination